The most terrifying spiders on the planet, known collectively as the treorrhines, are getting a much-needed new name.
The species, which is native to India, was once known as the Indian tremor spiders.
Researchers in the United States and India have created a gene therapy that could turn treorriences into a new class of living biological weapons that can wipe out the tremor.
The technique, known as a gene transfer, uses the gene that makes a tremor-like sensation in the muscles to transfer a specific DNA sequence into the treors.
It was pioneered in the 1950s and 1960s to treat polio.
But the new technique could potentially be used to treat other diseases and cancers.
Scientists from The New England Biolabs and Harvard Medical School in Boston and other institutions used a gene editing technique called CRISPR to change a gene called Hsp60, which codes for the receptor protein that detects tremor, to a new version that makes the treour-like feel in the body.
The researchers also used a protein called RAR-4, which sits on the same receptor that makes tremor feel, to make the treurreness feel more like pain.
The new gene transfer technique uses a gene that changes a gene code called HSP60 that codes for a receptor protein called HSp60.
The gene therapy could potentially help treat a number of diseases and tumors.
But scientists aren’t certain that the new gene-transfer technology will work in humans.
And the technique is still a bit experimental, since it uses gene therapy, not a drug.
Scientists at Harvard and The New Boston Biolabs have developed a gene-transmission technique called a gene modification using CRISP.
The technique uses gene editing using CRISA-RNA, a gene sequencing tool that can take a sample from the patient and create a digital copy of the DNA sequence.
It can also take a cell or tissue sample from a patient and insert the gene into it.
Because the gene modification works on the cell’s DNA, the new technology doesn’t need to be administered to patients to work.
As a result, the researchers say the technique could help treat disease without using drugs.
“This is a very exciting new approach for gene transfer to treat disease,” said study co-leader Jonathan Kallinen, a professor of molecular biology at The New Harvard Medical Schools.
One of the most exciting aspects of the technique, he said, is that the researchers can create new copies of the gene in the cells that are treated, rather than just taking a cell from the original patient and inserting it into a cell that has been treated.
Researchers hope that the gene therapy will be a new avenue for treatment of cancers.
They are also studying a gene targeting the protein receptor to kill tumors.
“The ability to target a single protein receptor is incredibly powerful in cancer therapies,” said David Mihalychik, the co-senior author of the study and an associate professor of biomedical engineering at The Harvard School of Engineering and Applied Sciences.
He is not affiliated with The NewBoston Biolabs.
This gene editing and gene modification technique has the potential to revolutionize the treatment of cancer.
And in a sense, it has already begun.
At the end of the 1990s, scientists in the U.S. and India were able to transfer the gene to a tumor cells.
But because the gene was not targeted to any particular cell type, it would not be able to kill the tumor.
The researchers then took a sample of the cancer cells and inserted the gene back into the cells.
After a few weeks, the cancer cell had completely recovered.
“Now, we can deliver a very specific target to the tumor cells,” said co-lead author and Harvard University postdoctoral researcher Seshasana Mohanty, who was also at the time a postdoctoral scholar at The Boston Brigham and Women’s Hospital.
“This gene therapy can deliver to the cancerous tumor cells the exact same DNA sequence that is being delivered to the original tumor cells.”
That means the new procedure could treat cancers in different ways.
If the gene-based gene therapy was to be used in humans, the team hopes to create a drug that can be given to patients and then implanted into the cancer to treat it.
It is not clear when this would happen, but the researchers have a number years to refine the gene transfer technology.
So far, the treatment has been in clinical trials and has not been approved by the Food and Drug Administration.
In a separate study, the Harvard team has also developed a technique called RNA-guided genome editing that uses CRISPs to edit the genomes of cells to correct a gene defect that causes tumors to grow abnormally.
Researchers are also working on a gene expression technology called gene delivery that could eventually help treat other cancers.
Another team led by David A. Katz, a Harvard Medical student and a researcher at The University of